Harmony Biosciences Holdings, Inc. (HRMY) financial statements and ratios from SEC XBRL: revenue $1.0B (TTM), net margin 18.3%, revenue growth 30.3% YoY, P/E 12.3. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $868.45M |
| Revenue (TTM) | $1.0B |
| Net Margin | 18.3% |
| Operating Margin (TTM) | 24.0% |
| Revenue Growth (YoY) | 30.3% |
| EPS Growth (YoY) | 88.4% |
| P/E Ratio | 12.3 |
| EV / EBITDA | 7.9 |
| Price / Book | 2.22 |
| Price / Sales | 2.31 |
| FCF Yield | 10.6% |
| Altman Z-Score | 5.32 (safe) |
| Piotroski F-Score | 5/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
HRMY overview · HRMY earnings · HRMY KPIs · HRMY documents · HRMY ownership · HRMY peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.